Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Sirius Therapeutics

Request full access

Advancing RNAi therapies globally to address significant cardiovascular risks

San Diego, United StatesFounded 2021Biotech & Life Sciences

About Sirius Therapeutics

Sirius is a forward-thinking biotech company that is focused on creating new RNAi (RNA interference) therapies for international markets. RNAi is a biological process where RNA molecules inhibit gene expression, effectively "silencing" targeted genes. This technology is used by Sirius to develop innovative treatments for cardiovascular diseases.

The company has recently received approval from China's National Medical Products Administration (NMPA) to conduct human clinical trials for SRSD101, a siRNA (small interfering RNA) therapeutic for Dyslipidemia, a condition characterized by an abnormal amount of lipids in the blood. In addition, Sirius has submitted an application to begin the first clinical trial of Factor XI siRNA, a long-lasting, next-generation anticoagulant for Thromboembolic disorders, which are conditions caused by blood clots.

Sirius operates in the global biopharmaceutical market, serving patients in need of new treatment options. The company's business model revolves around the research, development, and commercialization of RNAi therapies. It generates revenue through the successful development and subsequent sale of these innovative therapies.

The company's investors include OrbiMed, Creacion Ventures, Hankang Capital, and Delos Capital, all of which are well-known institutional investors with extensive experience in the biopharmaceutical industry. The leadership team at Sirius is made up of industry veterans who have held senior positions at multinational pharmaceutical companies such as Pfizer, AstraZeneca, Novartis, Arrowhead, Dicerna, and ONYX.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
21.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing May 2025 $50M $300M OrbiMed · Creacion Ventures · BioTrack Capital · Hankang Capital ↗
SERIES BOther financing Oct 2023 $60M $240M Hongyuan Capital · Hankang Capital · OrbiMed · Delos Capital ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Sirius Therapeutics website traffic

Latest recorded traffic for Sirius Therapeutics is 3K monthly website visits, up 11.1% over the last three months.

Latest monthly visits3K 3-month web change+11.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Sirius Therapeutics in the San Diego ecosystem

Live from Dealroom

The Sirius Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Hankang Capital
  • Hongyuan Capital
  • OrbiMed
  • Delos Capital
  • National Small and Medium Enterprise Development
  • Kangxi Global Investment Fund
  • Creacion Ventures
  • BioTrack Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Sirius Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Sirius Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.